Skip to content

Home - Media - Press releases - 2003    
12 December 2003
ASTRAZENECA PRILOSEC® PATENTS UPHELD BY FEDERAL APPEALS COURT

AstraZeneca today announced that a three judge panel of the United States Court of Appeals for the Federal Circuit upheld the October 2002 decision by U.S. District Court Judge Barbara S. Jones, finding that Andrx, Genpharm and Cheminor infringed AstraZeneca’s patents for Prilosec® (omeprazole), and that the two formulation patents are not invalid. The Court also upheld the judgment that Kudco’s formulation did not infringe.
AstraZeneca is pleased with the Court’s decision upholding the validity of our patents, again reaffirming the strength of our intellectual property.

Prilosec is a treatment for acid-related stomach disorders.



Further enquiries to:

Media Enquiries:
Steve Brown, +44 (0) 207 304 5033
Edel McCaffrey, +44 (0) 207 304 5034

Investor Enquiries:
Mina Blair-Robinson, +44 (0) 207 304 5084
Jonathan Hunt, +44 (0) 207 304 5087
AstraZeneca websites
Search
 Terms of use  Privacy policy    © AstraZeneca PLC 2003 - 2008